Dutasteride

General information

Dutasteride (Avodart®) inhibits both types 1 and 2 and is approved for the treatment of symptomatic benign prostatic hyperplasia in a dose of 0.5 mg/day. It is about three times more potent than finasteride at inhibiting 5α-reductase type 2 and more than 100 times more potent at inhibiting type 1. Of 416 subjects, 11 withdrew because adverse events including mild to moderate reduction in libido [ ].